AlphAIAlphAI — Financial news for AI agents
investing.comSEP 151 min read$NAMS

NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock

NewAmsterdam Pharma (NAMS) shares rose 4% after CEO Michael H. Davidson bought 10,000 shares at $22.65 each, totaling $226.5K. Davidson now holds 792,923 shares directly and 285,715 indirectly. The purchase was disclosed in an SEC Form 4 filing. Investing.com's AI tool, ProPicks AI, evaluates NAMS among other companies using financial metrics.

Original reporting
investing.com
Published Sep 15, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NAMS
Bullish
medium confidence
Mentioned
$NAMS
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NAMSBullishLow
01

Why it matters

The insider purchase provides a fresh data point for traders assessing short‑term sentiment.

02

Market read

Primary disclosure of insider buying; modest relevance for short‑term traders.

03

What to watch

Potential upcoming clinical data could be the real driver, not the insider trade.

Relevance 4/10Novelty 5/10Timing: after‑hours today

Background

Form 4 filing reveals insider activity; article includes AI‑generated commentary unrelated to the core news.

Company-level read

Ticker impact

$NAMSBullishMedium confidence
Context

CEO Michael H. Davidson purchased 10,000 shares at $22.65, disclosed via Form 4 filing.

Expected impact

Potential modest uptick in after‑hours trading, limited longer‑term effect.

Evidence & confidence

The buy amount (~$226.5K) is modest for a mid‑cap biotech; market may view it positively but impact is likely limited.

Market effects

Sector

May provide slight confidence boost to biotech sector peers.

Regional

Limited to US markets where NAMS trades.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Buyers may view the small insider purchase as insignificant and ignore it.

Key entities

  • person
    Michael H. Davidson

    CEO and director of NewAmsterdam Pharma

  • company
    NewAmsterdam Pharma Co N.V.

    Biotech firm listed on NASDAQ under ticker NAMS

Read at source← All news

Related articles

SEP 29
$NAMSLowAI 8/10

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeabl

SEC EDGAR 8-K1 min
SEP 23
$NAMSMedAI 9/10

Is NewAmsterdam Pharma (NAMS) Undervalued After Its First Obicetrapib Approval?

NewAmsterdam Pharma (NAMS) received European Commission approval for its cholesterol drug obicetrapib, marking its first global regulatory approval. The stock has seen a recent bounce, up 3.28% to $23.32, following a period of decline. Analysts suggest the company may be undervalued with an implied fair value of $50.92, but risks include potential trial failures and equity dilution.

simplywall.st2 min
SEP 21
$NAMSMedAI 8/10

NewAmsterdam Pharma Company N.V. along with its partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo…

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Ev

SEC EDGAR 8-K2 min
AUG 5
$NAMSMed

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q20

SEC EDGAR 8-K7 min